Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Language Podcast: ESMO China Data, Annual CDE Report, Shanghai Biopharma Week

Regulatory Trends, Latest Data Readouts And More

Executive Summary

Topics in this latest Chinese-language podcast include the China Center for Drug Evaluation's annual IND and NDA report, highlights of Chinese companies' data readouts at ESMO, and policy signals from the International Biopharma Industry Week Shanghai.

Chinese oncology developers including BeiGene, Ltd., Jiangsu Hengrui Medicine Co., Ltd. and Shanghai Junshi Biosciences Co., Ltd. all released new clinical data during the recent European Society for Medical Oncology (ESMO) meeting.

What were some of the highlights and notable results, in particular against emerging targets such as KRAS G12D? (Also see "ESMO 23: Kelun/Merck, Hansoh ADCs Impress With Early Data In Breast Cancer" - Scrip, 20 Oct, 2023.)

In other recent hot China biopharma topics covered in this Chinese-language podcast, China's Center for Drug Evaluation released its annual report for 2022, which highlighted several key trends in clinical trial and new drug approval activity in the country. (Also see "China New Drug Trials Momentum Tapering, Regulatory Changes Looming" - Pink Sheet, 16 Oct, 2023.)

Meanwhile, the Shanghai municipal government organized its major international biopharma week for the third year in a row from 16-20 October. Shanghai-based Scrip senior editor Dexter Yan makes some observations on his in-person attendance at the event. 

If you have any suggestions, comments or ideas, please contact the authors at the email addresses above. 

This and all our other podcasts are available on the Citeline channel on Apple PodcastsGoogle PodcastsSoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

在今年的ESMO上,中国生物药企有何亮点?比如在ADC药物的研发上,有哪些早期临床数据读出?除了ADC药物,还有哪些值得关注的临床结果,比如在KRAS G12D,或者三期临床数据读出方面?





Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts